|
The Effect of 5-alpha Reductase on Testosterone in Men Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about The Effect of 5-alpha Reductase on Testosterone in Men conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. The Effect of 5-alpha Reductase on Testosterone in Men Clinical research trials and The Effect of 5-alpha Reductase on Testosterone in Men medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like The Effect of 5-alpha Reductase on Testosterone in Men. The Effect of 5-alpha Reductase on Testosterone in Men Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a The Effect of 5-alpha Reductase on Testosterone in Men clinical trial. Test subjects typically obtain the finest healthcare available for their The Effect of 5-alpha Reductase on Testosterone in Men condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Effect of 5-alpha Reductase on Testosterone in Men  The Effect of 5-alpha Reductase on Testosterone in Men
The Effect of 5-alpha Reductase on Testosterone in Men
For Condition: Sex Disorders
Status: Recruiting
Sponsor(s): National Institute of Child Health and Human Development (NICHD) ,
Synopsis: The enzyme 5-alpha reductase is present in small amounts in muscle and converts testosterone to dihydrotestosterone (DHT). Testosterone affects lean body tissue, muscle size, muscle strength, and sexual function in men. This study will evaluate how 5-alpha reductase influences the effects of testosterone in young healthy men.
Details: Testosterone, the predominant circulating androgen in men, serves as the active hormone in some target tissues; however, testosterone effects in other target organs require its conversion to two active metabolites, estradiol 17-beta and DHT. The role of 5-alpha reductase in mediating testosterone's effects on muscle and sexual function remains unclear. This study will determine whether 5-alpha reduction of testosterone to DHT is necessary for mediating effects on fat-free mass, muscle size, muscle strength, and leg power in men. The study will also evaluate the necessity of 5-alpha reductase for maintenance of androgen effects on sexual function (sexual desire, overall sexual activity, nocturnal penile tumescence [NPT], response to visual erotic stimulus, and penile rigidity) in men. Participants in this study will be treated with a drug to suppress endogenous testosterone production. Participants will then be randomly assigned to receive either testosterone and placebo or testosterone and the 5-alpha reductase inhibitor duasteride. Testosterone will be administered weekly; duasteride and placebo will both be administered daily. Diet and exercise will be standardized across both groups. Participants will be assessed at study entry and Week 20. Assessments will include measurements such as a DEXA scan, MRI scan, and muscle performance and sexual function tests. Participants will also have blood tests for safety monitoring; blood tests will include measures of hematocrit, liver enzymes (AST and ALT), prostate specific antigen (PSA), and cholesterol.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 21 Years/40 Years
Genders: Male
Protocol Entry Criteria: Inclusion Criteria - General good health and capable of undergoing strength testing - Normal testosterone (300-1100 ng/dL), LH, and FSH levels Exclusion Criteria - Currently participating in competitive sports - Mental state that would preclude complete understanding of the protocol and compliance - Disorder known to cause or be associated with hypogonadism (e.g., pituitary tumors, hyperprolactinemia, HIV infection, or Klinefelter's Syndrome) - More than 20% over ideal body weight - Disabilities that would prevent participation in strength testing (e.g., amputation of limbs, blindness, severe arthritis, angina, or neurologic disorders such as Parkinson's disease, stroke, or myopathy) - Uncontrolled hypertension, diabetes, congestive heart failure, or chronic obstructive lung disease - Alcohol or drug dependence in the 6 months prior to study entry - Disorders that might be exacerbated by androgen treatment (e.g., benign prostatic hyperplasia or prostate cancer, erythrocytosis [hematocrit > 51% at baseline], or sleep apnea assessed by Berlin's questionnaire) - Serum PSA levels > 4 microg/L - AST, ALT, or alkaline phosphatase elevation greater than three times the upper limit of normal - Creatinine greater than 2 mg/dL - Medications that might affect muscle or bone metabolism (e.g., glucocorticoid, rhGH, androgenic steroids, oral androgen precursors such as androstenedione or DHEA) or androgen metabolism, action, or clearance (e.g., dilantin, phenobarbitol, aldactone, flutamide, finasteride)
Total Enrollment: 184
Location and Contact Information:
Overall Study Official:
ShalenderBhasin, Principal Investigator, Charles R. Drew University
Charles R. Drew University *Recruiting*
Los Angeles, California, 90059
United States
Recruiting Shalender Bhasin 323-563-9353
Additional Information:
Study ID Numbers: R01 HD43348-01;
Study Start Date: August 2003
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00070733
Other Sex Disorders Studies:
1. The Effect of 5-alpha Reductase on Testosterone in Men
Related Studies:
Other Sex Disorders Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
The Effect of 5-alpha Reductase on Testosterone in Men
|
|
|
|
|
|
|
|
